一项评估皮下注射 Emicizumab 在出生至 12 个月大的无抑制剂血友病 A 参与者中的疗效、安全性、药代动力学和药效学的研究 (HAVEN 7)
一项 IIIb 期、多中心、开放标签、单组研究,旨在评估皮下注射 Emicizumab 在出生至 12 个月大的无抑制剂血友病 A 患者中的疗效、安全性、药代动力学和药效学
This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A (intrinsic factor VIII [FVIII] level <1%) without FVIII inhibitors. The study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 milligrams per kilogram of body weight (mg/kg) once every 2 weeks (Q2W) for 52 weeks. After 1 year of treatment, participants will continue to receive emicizumab (1.5 mg/kg once every week [QW], 3 mg/kg Q2W or 6 mg/kg once every 4 weeks [Q4W]) over a 7-year long-term follow-up period under this study frame.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Tel HaShomer、以色列、5262100
- Sheba Medical Center - National Hemophilia Center
-
-
-
-
Ontario
-
Ottawa、Ontario、加拿大、K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto、Ontario、加拿大、M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Johannesburg、南非、2193
- Charlotte Maxeke Johannesburg Hospital
-
-
-
-
-
Adana、土耳其(türkiye)、01130
- Adana Acibadem Hospital
-
Ankara、土耳其(türkiye)、06100
- Hacettepe University Medical Faculty
-
Izmir、土耳其(türkiye)、35100
- Ege University, School of Medicine
-
Samsun、土耳其(türkiye)、55139
- Ondokuz Mayis Univ. Med. Fac.
-
-
-
-
-
Vienna、奥地利、1090
- Medizinische Universität Wien
-
-
-
-
São Paulo
-
Ribeirão Preto、São Paulo、巴西、14051-140
- Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
-
-
-
-
-
Bonn、德国、53127
- Universitätsklinikum Bonn
-
Mörfelden-Walldorf、德国、64546
- Hämophilie-Zentrum Rhein Main GmbH
-
-
-
-
Campania
-
Naples、Campania、意大利、80123
- AORN Santobono Pausilipon
-
-
Emilia-Romagna
-
Parma、Emilia-Romagna、意大利、43126
- AOU di Parma
-
-
Lombardy
-
Milan、Lombardy、意大利、20122
- IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
-
Tuscany
-
Florence、Tuscany、意大利、50134
- AOU Careggi
-
-
-
-
-
Brussels、比利时、1200
- Cliniques Universitaires St-Luc
-
Leuven、比利时、3000
- UZ Leuven Gasthuisberg
-
-
-
-
-
Paris、法国、75015
- Groupe Hospitalier Necker Enfants Malades
-
-
-
-
New South Wales
-
Westmead、New South Wales、澳大利亚、2145
- The Children's Hospital at Westmead
-
-
Victoria
-
Parkville、Victoria、澳大利亚、3052
- Royal Children's Hospital
-
-
Western Australia
-
Nedlands、Western Australia、澳大利亚、6009
- Perth Children's Hospital
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85016
- Phoenix Children's Hospital
-
-
California
-
Los Angeles、California、美国、90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora、Colorado、美国、80045
- University of Colorado Denver, Children's Hospital
-
-
Louisiana
-
New Orleans、Louisiana、美国、70112
- Tulane University Health Sciences Center
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109-0934
- University of Michigan
-
-
Washington
-
Seattle、Washington、美国、98105
- Seattle Children's Hospital
-
-
-
-
-
Glasgow、英国、G51 4TF
- Queen Elizabeth University Hospital
-
-
-
-
-
Madrid、西班牙、28046
- Hospital Universitario la Paz
-
Seville、西班牙、41013
- Hospital Universitario Virgen del Rocio
-
-
Barcelona
-
Esplugues de Llobregat、Barcelona、西班牙、08950
- Hospital Sant Joan de Deu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age from birth to ≤12 months at time of informed consent
- Body weight ≥3 kilograms (kg) at time of informed consent. Patients with a lower body weight can be enrolled after they have reached a body weight of 3 kg. Premature babies (gestational age <38 weeks) may be enrolled as long as they have reached a body weight of 3 kg. For premature babies, the corrected gestational age should be reported.
- Mandatory receipt of vitamin K prophylaxis according to local standard practice
- Diagnosis of severe congenital hemophilia A (intrinsic FVIII level <1%)
- A negative test for FVIII inhibitor (i.e., <0.6 Bethesda units [BU]/mL) locally assessed during the 2-week screening period
- No history of documented FVIII inhibitor (i.e., <0.6 BU/mL), FVIII drug-elimination half-life <6 hours, or FVIII recovery <66%
- Previously untreated patients or minimally treated patients (i.e., up to 5 days of exposure with hemophilia-related treatments, such as plasma-derived FVIII, recombinant FVIII, fresh frozen plasma, cryoprecipitate, or whole blood products)
- Documentation of the details of the hemophilia-related treatments received since birth
- Documentation of the details of the bleeding episodes since birth
- For patients from birth to <3 months of age at the time of study entry: no evidence of active intracranial hemorrhage, as confirmed by a negative cranial ultrasound at screening irrespective of delivery mode
- Adequate hematologic, hepatic, and renal function, as defined in the protocol
- For parents/caregivers: willingness and ability to comply with the study protocol requirements, scheduled visits, treatment plans, laboratory tests, completion of applicable questionnaires, and other study procedures
Exclusion Criteria:
- Inherited or acquired bleeding disorder other than severe hemophilia A
- Use of systemic immunomodulators (e.g., interferon) at enrollment or planned use during the study
- Receipt of any of the following: Prior use of emicizumab prophylaxis including investigational or commercial emicizumab; An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 drug-elimination half-lives of last drug administration; A non-hemophilia-related investigational drug within the last 30 days or 5 drug-elimination half-lives, whichever is shorter; An investigational drug concurrently
- Current active severe bleed, such as intracranial hemorrhage
- Planned surgery (excluding minor procedures, e.g., circumcision, CVAD placement) during the study
- History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
- Patients who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA, such as thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome) in the investigator's judgment
- Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis in patients for whom anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
- Any hereditary or acquired maternal condition that may predispose the patient to thrombotic events (e.g., inherited thrombophilias antiphospholipid syndrome)
- Other diseases (e.g., certain autoimmune diseases) that may increase risk of bleeding or thrombosis
- Known infection with HIV, hepatitis B virus, or hepatitis C virus
- Serious infection requiring antibiotics or antiviral treatments within 14 days prior to screening
- Concurrent disease, treatment, abnormality in clinical laboratory tests, vital signs measurements, or physical examination findings that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patient's safe participation in and completion of the study or interpretation of the study results
- Unwillingness of the parent or caregiver to allow receipt of blood or blood products, or any standard-of-care treatment for a life-threatening condition
- Any other medical, social, or other condition that may prevent adequate compliance with the study protocol in the opinion of the investigator
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:艾美珠单抗
|
Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control. At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period. During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Model-Based Annualized Bleeding Rate for Treated Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of treated bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Mean Calculated Annualized Bleeding Rate for Treated Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Median Calculated Annualized Bleeding Rate for Treated Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Model-Based Annualized Bleeding Rate for All Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of all bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Mean Calculated Annualized Bleeding Rate for All Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Median Calculated Annualized Bleeding Rate for All Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of treated spontaneous bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Model-Based Annualized Bleeding Rate for Treated Joint Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of treated joint bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
|
Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds
大体时间:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. |
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Emicizumab 的血浆谷浓度(谷)
大体时间:在第 1、3、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周给药前
|
在第 1、3、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周给药前
|
|
|
抗 Emicizumab 抗体的发生率
大体时间:第 1、5、17、29、41 和 53 周,以及之后的临床指征直至研究完成(最多 8 年)
|
第 1、5、17、29、41 和 53 周,以及之后的临床指征直至研究完成(最多 8 年)
|
|
|
长期随访期间指定时间点的血友病关节健康评分 (HJHS) 总分
大体时间:随访第 4、5、6、7 和 8 年
|
随访第 4、5、6、7 和 8 年
|
|
|
长期随访期间特定时间点特定关节的磁共振成像 (MRI) 评分
大体时间:随访第 5 年和第 8 年
|
随访第 5 年和第 8 年
|
|
|
不良事件的发生率和严重程度,严重程度根据世界卫生组织 (WHO) 毒性分级标准确定
大体时间:从首次服用艾美珠单抗直至研究完成(8 年)
|
从首次服用艾美珠单抗直至研究完成(8 年)
|
|
|
血栓栓塞事件的发生率
大体时间:从首次服用艾美珠单抗直至研究完成(8 年)
|
从首次服用艾美珠单抗直至研究完成(8 年)
|
|
|
血栓性微血管病的发生率
大体时间:从首次服用艾美珠单抗直至研究完成(8 年)
|
从首次服用艾美珠单抗直至研究完成(8 年)
|
|
|
注射部位反应的发生率和严重程度,严重程度根据世界卫生组织毒性分级标准确定
大体时间:从首次服用艾美珠单抗直至研究完成(8 年)
|
从首次服用艾美珠单抗直至研究完成(8 年)
|
|
|
严重超敏反应、过敏反应和类过敏事件的发生率
大体时间:从首次服用艾美珠单抗直至研究完成(8 年)
|
从首次服用艾美珠单抗直至研究完成(8 年)
|
|
|
导致研究药物中止的不良事件发生率
大体时间:从首次服用艾美珠单抗直至研究完成(8 年)
|
从首次服用艾美珠单抗直至研究完成(8 年)
|
|
|
脉搏率随时间相对于基线的变化
大体时间:基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
|
|
呼吸频率随时间变化相对于基线的变化
大体时间:基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
|
|
体温随时间相对基线的变化
大体时间:基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
|
|
收缩压随时间相对于基线的变化
大体时间:基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
|
|
舒张压随时间相对于基线的变化
大体时间:基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
基线、第 1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49 和 53 周,以及 7 年随访期间每年一次学习完成前的期限(最长 8 年)
|
|
|
Number of Participants According to Hematology and Serum Chemistry Laboratory Test Result Shifts From Baseline WHO Grade to the Highest WHO Grade Post-Baseline
大体时间:Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53
|
Laboratory parameters for hematology and blood chemistry were measured at baseline and over time, and the values were compared with a standard reference range. Values outside the standard reference range were considered laboratory abnormalities and graded according to the World Health Organization (WHO) toxicity grading scale, ranging from lowest (Grade 1) to greatest (Grade 4) deviation from standard in the direction indicated for the abnormality (i.e., below (Low) or above (High) the reference range; 'Not Low' and 'Not High' indicate values within the reference range). Participants were categorized according to their laboratory test result shift from baseline WHO grade to highest WHO grade at any point post-baseline (up to Week 53) for each parameter. 'Missing' indicates that the test result was not available. |
Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53
|
|
Incidence of De Novo Development of Factor VIII Inhibitors
大体时间:As clinically indicated from baseline until study completion (up to 8 years)
|
As per the protocol, after any 3 exposure days to FVIII or a block of FVIII exposure days (e.g., a block is defined as a minimum of two consecutive doses of FVIII) administered for treatment of a bleed, a surgical procedure, or other (e.g., preventative doses before activity), one plasma sample for anti-FVIII antibodies (for centralized analysis) had to be collected 14 days after the final dose of FVIII administered. |
As clinically indicated from baseline until study completion (up to 8 years)
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
出版物和有用的链接
一般刊物
- Hart DP. Commentary on "Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach" - Will we ever be able to avoid inhibitor formation in hemophilia A? J Thromb Haemost. 2021 Sep;19(9):2125-2126. doi: 10.1111/jth.15404. No abstract available.
- Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jimenez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024 Apr 4;143(14):1355-1364. doi: 10.1182/blood.2023021832.
- Lopez-Jaime FJ, Benitez O, Diaz Jordan BL, Montano A, Coll J, Quintana Paris L, Gomez-Del Castillo Solano MDC. Expert opinion paper on the treatment of hemophilia a with emicizumab. Hematology. 2023 Dec;28(1):2166334. doi: 10.1080/16078454.2023.2166334.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- MO41787
- 2020-001733-12 (EudraCT编号)
- 2023-505964-13-00 (注册表标识符:EU CT Number)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.